Habbema JD - Search Results

1

Effect of screening and adjuvant therapy on mortality from breast cancer.

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Berry DA, et al. Among authors: habbema jd. N Engl J Med. 2005 Oct 27;353(17):1784-92. doi: 10.1056/NEJMoa050518. N Engl J Med. 2005. PMID: 16251534 Free article.

2

Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative?

Habbema JD, Tan SY, Cronin KA. Habbema JD, et al. J Natl Cancer Inst Monogr. 2006;(36):105-11. doi: 10.1093/jncimonographs/lgj014. J Natl Cancer Inst Monogr. 2006. PMID: 17032900

3

Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience.

Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ. Habbema JD, et al. J Natl Cancer Inst Monogr. 2006;(36):122-6. doi: 10.1093/jncimonographs/lgj017. J Natl Cancer Inst Monogr. 2006. PMID: 17032902 No abstract available.

4

Clarifying differences in natural history between models of screening: the case of colorectal cancer.

van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM. van Ballegooijen M, et al. Among authors: habbema jd. Med Decis Making. 2011 Jul-Aug;31(4):540-9. doi: 10.1177/0272989X11408915. Epub 2011 Jun 14. Med Decis Making. 2011. PMID: 21673187 Free PMC article.

5

Models in the development of clinical practice guidelines.

Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ. Habbema JD, et al. Ann Intern Med. 2014 Dec 2;161(11):812-8. doi: 10.7326/M14-0845. Ann Intern Med. 2014. PMID: 25437409

6

The MISCAN-Fadia continuous tumor growth model for breast cancer.

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. Tan SY, et al. Among authors: habbema jd. J Natl Cancer Inst Monogr. 2006;(36):56-65. doi: 10.1093/jncimonographs/lgj009. J Natl Cancer Inst Monogr. 2006. PMID: 17032895

7

How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment.

Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. Vogelaar I, et al. Among authors: habbema jd. Cancer. 2006 Oct 1;107(7):1624-33. doi: 10.1002/cncr.22115. Cancer. 2006. PMID: 16933324 Free article.

8

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Lansdorp-Vogelaar I, et al. Among authors: habbema jd. J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319. Epub 2009 Sep 24. J Natl Cancer Inst. 2009. PMID: 19779203 Free PMC article.

9

Informed choice on Pap smear still limited by lack of knowledge on the meaning of false-positive or false-negative test results.

Korfage IJ, van Ballegooijen M, Wauben B, Habbema JD, Essink-Bot ML. Korfage IJ, et al. Among authors: habbema jd. Patient Educ Couns. 2011 Nov;85(2):214-8. doi: 10.1016/j.pec.2010.12.014. Epub 2011 Jan 26. Patient Educ Couns. 2011. PMID: 21269793 Free article.

10

Models in the development of clinical practice guidelines.

Habbema JD, Wilt TJ, Etzioni R. Habbema JD, et al. Ann Intern Med. 2015 Apr 7;162(7):530-1. doi: 10.7326/L15-5075-2. Ann Intern Med. 2015. PMID: 25845011 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

469 results

Search Page